Upexi (UPXI) Competitors $12.71 +0.71 (+5.92%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$12.65 -0.06 (-0.47%) As of 07:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock UPXI vs. ARQT, DYN, EWTX, CNTA, ADPT, JANX, ETNB, MESO, EVO, and SPRYShould you be buying Upexi stock or one of its competitors? The main competitors of Upexi include Arcutis Biotherapeutics (ARQT), Dyne Therapeutics (DYN), Edgewise Therapeutics (EWTX), Centessa Pharmaceuticals (CNTA), Adaptive Biotechnologies (ADPT), Janux Therapeutics (JANX), 89bio (ETNB), Mesoblast (MESO), Evotec (EVO), and ARS Pharmaceuticals (SPRY). These companies are all part of the "pharmaceutical products" industry. Upexi vs. Its Competitors Arcutis Biotherapeutics Dyne Therapeutics Edgewise Therapeutics Centessa Pharmaceuticals Adaptive Biotechnologies Janux Therapeutics 89bio Mesoblast Evotec ARS Pharmaceuticals Upexi (NASDAQ:UPXI) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap business services companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, community ranking, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends. Does the media favor UPXI or ARQT? In the previous week, Arcutis Biotherapeutics had 2 more articles in the media than Upexi. MarketBeat recorded 11 mentions for Arcutis Biotherapeutics and 9 mentions for Upexi. Arcutis Biotherapeutics' average media sentiment score of 0.93 beat Upexi's score of 0.42 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Upexi 1 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arcutis Biotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, UPXI or ARQT? Upexi has a beta of -0.3, suggesting that its stock price is 130% less volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500. Which has higher valuation & earnings, UPXI or ARQT? Upexi has higher earnings, but lower revenue than Arcutis Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUpexi$16.56M29.10-$23.66MN/AN/AArcutis Biotherapeutics$212.82M7.69-$262.14M-$1.04-13.20 Is UPXI or ARQT more profitable? Upexi has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -140.97%. Upexi's return on equity of 0.00% beat Arcutis Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets UpexiN/A N/A N/A Arcutis Biotherapeutics -140.97%-119.11%-45.95% Do analysts recommend UPXI or ARQT? Arcutis Biotherapeutics has a consensus price target of $18.80, suggesting a potential upside of 36.93%. Given Arcutis Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Upexi.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Upexi 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Arcutis Biotherapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Does the MarketBeat Community favor UPXI or ARQT? Arcutis Biotherapeutics received 70 more outperform votes than Upexi when rated by MarketBeat users. Likewise, 68.22% of users gave Arcutis Biotherapeutics an outperform vote while only 37.50% of users gave Upexi an outperform vote. CompanyUnderperformOutperformUpexiOutperform Votes337.50% Underperform Votes562.50% Arcutis BiotherapeuticsOutperform Votes7368.22% Underperform Votes3431.78% Do institutionals & insiders have more ownership in UPXI or ARQT? 5.7% of Upexi shares are held by institutional investors. 31.6% of Upexi shares are held by insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryArcutis Biotherapeutics beats Upexi on 9 of the 16 factors compared between the two stocks. Get Upexi News Delivered to You Automatically Sign up to receive the latest news and ratings for UPXI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UPXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UPXI vs. The Competition Export to ExcelMetricUpexiMedicinals & botanicals IndustryBusiness SectorNASDAQ ExchangeMarket Cap$481.90M$1.20B$14.33B$8.63BDividend YieldN/AN/A2.60%4.18%P/E RatioN/A12.3834.3520.06Price / Sales29.1010.75312.32157.10Price / CashN/A10.4030.9334.64Price / Book4.461.505.464.70Net Income-$23.66M-$56.07M$195.72M$247.88M7 Day Performance6.63%0.87%2.66%2.63%1 Month Performance19.45%0.07%3.69%6.36%1 Year Performance28.13%-31.77%24.28%14.05% Upexi Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UPXIUpexi1.0865 of 5 stars$12.71+5.9%N/A+29.5%$481.90M$16.56M0.00130Short Interest ↑Gap UpARQTArcutis Biotherapeutics2.1035 of 5 stars$14.21-1.1%$18.80+32.3%+76.5%$1.69B$212.82M-7.94150Gap UpDYNDyne Therapeutics2.6924 of 5 stars$14.40-2.0%$45.54+216.2%-52.9%$1.64BN/A-4.04100Analyst ForecastHigh Trading VolumeEWTXEdgewise Therapeutics2.861 of 5 stars$15.26+0.1%$39.78+160.7%-7.9%$1.60BN/A-10.1760Positive NewsCNTACentessa Pharmaceuticals3.7353 of 5 stars$11.94+0.2%$27.89+133.6%+33.9%$1.59B$15M-7.80200Positive NewsHigh Trading VolumeADPTAdaptive Biotechnologies2.7262 of 5 stars$10.45+3.6%$9.83-5.9%+208.1%$1.59B$189.53M-9.59790Positive NewsJANXJanux Therapeutics2.3999 of 5 stars$25.94-1.0%$95.25+267.2%-39.4%$1.55B$9.34M-22.1730Positive NewsAnalyst RevisionETNB89bio2.7463 of 5 stars$10.57+3.1%$26.43+150.0%+15.7%$1.54BN/A-3.6340News CoverageAnalyst ForecastAnalyst RevisionMESOMesoblast2.3496 of 5 stars$11.85+0.5%$18.00+51.9%+62.8%$1.51B$5.67M0.0080News CoverageAnalyst RevisionEVOEvotec2.1014 of 5 stars$4.12+1.7%$5.93+44.0%-10.5%$1.46B$788.22M0.004,200SPRYARS Pharmaceuticals3.4159 of 5 stars$14.53+0.3%$31.00+113.4%+59.9%$1.43B$97.12M-28.4990Positive NewsAnalyst Revision Related Companies and Tools Related Companies ARQT Alternatives DYN Alternatives EWTX Alternatives CNTA Alternatives ADPT Alternatives JANX Alternatives ETNB Alternatives MESO Alternatives EVO Alternatives SPRY Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UPXI) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Upexi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Upexi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy UPXI Stock Free UPXI Stock Alerts